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STING-associated vasculopathy with onset in infancy (SAVI) is an autosomal dominant
disorder due to gain-of-function mutations in STING1, also known as TMEM173,
encoding for STING. It was reported as a vasculopathy of infancy. However, since its
description a wider spectrum of associated manifestations and disease-onset has been
observed. We report a kindred with a heterozygous STING mutation (p.V155M) in which
the 19-year-old proband suffered from isolated adult-onset ANCA-associated vasculitis.
His father suffered from childhood-onset pulmonary fibrosis and renal failure attributed
to ANCA-associated vasculitis, and died at the age of 30 years due to respiratory failure.
In addition, an overview of the phenotypic spectrum of SAVI is provided highlighting (a)
a high phenotypic variability with in some cases isolated manifestations, (b) the potential
of adult-onset disease, and (c) a novel manifestation with ANCA-associated vasculitis.
Keywords: SAVI, vasculopathy, glomerulonephritis, primary immunodeficiency, interferonopathy
INTRODUCTION
STING-associated vasculopathy with onset in infancy (SAVI) was initially reported as a
vasculopathy of infancy. However, since its initial description, a wider spectrum of associated
manifestations and disease-onset has been observed. We report a kindred with isolated adult-
onset ANCA-associated vasculitis, extending the phenotypic spectrum. In addition, we provide
a comprehensive overview of the phenotypic spectrum of SAVI by reviewing the other 54 cases
reported in literature. Our findings highlight (a) a high phenotypic variability with in some cases
isolated manifestations, (b) the potential of adult-onset disease, and (c) a novel manifestation with
ANCA-associated vasculitis.
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CASE REPORT
A 19-year-old Caucasian male (Figure 1A, III.1, and
Supplementary Document E1 and Supplementary Table
E1, available in the online repository) presented with exertional
dyspnea and fatigue. Eleven months prior to the current
presentation he reported an episode of hemoptysis, but left
without further investigation. Initial blood results demonstrated
a profound microcytic (MCV 76.8 fL, reference 82–98 fL)
anemia (Hb 6.3 g/dL, reference 13–16 g/dL) with iron deficiency
(transferrin saturation 6.6%, 20–50%) and mildly elevated
C-reactive protein (23.1 mg/L, reference 0–5 mg/L). Gastro-
and colonoscopy did not reveal gastrointestinal bleeding. He
received red blood cell transfusion and was discharged with
iron and vitamin supplements. One week later, he presented
with a painful, red eye and decreased vision. A diagnosis of
iritis was made. Further work-up revealed the presence of
myeloperoxidase (MPO) specific antineutrophil cytoplasmic
antibodies (ANCA, titer 1/640) with proteinuria (1.76 g/24 h,
reference <0.14 g/24 h), pyuria (25/µL, reference <10/µL) and
hematuria (185/µL, reference <10/µL, 88% dysmorphic) on
urinalysis. Subsequent renal biopsy identified a pauci-immune
focal crescentic and necrotizing glomerulonephritis with
mesangial C3 deposition (Figure 1C). His father (Figure 1A, II.2)
had suffered from childhood-onset pulmonary fibrosis and renal
failure attributed to ANCA-associated vasculitis with progressive
pauci-immune intra- and extra-capillary glomerulonephritis,
dying at the age of 30 years due to respiratory failure (Figure 1C).
The patient’s brother died in utero with renal vein thrombosis as
the only notable finding on autopsy. Given the family history,
whole-exome sequencing was performed, revealing a known
pathogenic c.463G > A (p.V155M) mutation in STING1 (1).
Sanger sequencing confirmed the presence of this variant in the
proband and his father but not in his healthy mother (Figure 1A).
Interferon (IFN) stimulated genes (ISG) expression, determined
by qPCR on patient’s whole blood RNA was increased compared
to controls (Figure 1B). Hence, a diagnosis of autosomal
dominant STING-associated vasculopathy with onset in infancy
(SAVI) (1) was made, presenting in our proband as adult-onset
isolated renal and ocular ANCA-associated vasculitis.
REVIEW OF THE LITERATURE
To further outline the phenotypic spectrum, the clinical
manifestations, genetics and treatment modalities in 56
genetically confirmed SAVI patients (including our kindred)
was reviewed (Figure 2 and Supplementary Figure E1 and
Supplementary Table E1, available in the online repository).
Disease-onset usually manifested early in life (35.7% in
neonatal life and up to 92.9% presenting before adulthood).
Adult-onset SAVI had only been described in two other patients,
a male with a long-standing history of arthralgia and recurrent
elevated inflammatory parameters and a 20-year-old female
with interstitial lung disease (ILD), progressing to lung fibrosis
requiring lung transplantation (2, 3). SAVI has a high mortality
rate, with 18% of reported patients deceased at the time of
publication, mostly due to respiratory complications and before
adulthood (Figure 2) (1–3).
Across the 56 surveyed patients, vasculopathy resulting
from vasculitis and endothelial cell death is a hallmark of
SAVI mostly affecting the skin, lungs and central nervous
FIGURE 1 | (A) Pedigree: c.463G > A, p.V155M mutation in STING1 was confirmed by Sanger in proband III.1 and II.2. (B) Relative quantification (RQ) of interferon
stimulated genes on qPCR of whole blood RNA of III.1 (green) and 27 controls (blue). (C) Renal biopsy of II.2 (left panel) and III.1 (right panel) showing extra and
intracapillary with glomerulonephritis cellular (C) and fibrocellular (FC) crescents.
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FIGURE 2 | Clinical and genetic synopsis of 56 SAVI patients. (A) Schematic representation of potential clinical presentations (B) Schematic representation of the
STING protein, consisting of 4 transmembrane domains (TM1-4, blue), dimerization domain (DD, green), cGAMP binding domain (CBD, black bar) and C-terminal tail
domain (CTT, orange). Gain-of-function mutations are indicated in black with number of cases reported underneath (C) Age of onset, n = 52 reported (D) Number of
associated features, n = 56 reported (E) Mortality in SAVI patients, n = 56 reported.
system (1, 4). Clinically this commonly manifested as chilblains
(33.9%), telangiectasia (32.1%), livedo reticularis (32.1%)
and Raynaud phenomena (12.5%). Sometimes, more severe
manifestations occurred such as acral ischemia necessitating
amputations (21.4%) or ischemic/hemorrhagic stroke (5.4%) (1,
4). Cutaneous manifestations were common in SAVI, mostly
with erythematous, malar, maculopapular rashes, and acral
violaceous plaques (46.4%) with or without concomitant nail
dystrophy (21.4%). Skin biopsy (performed in 37.5%) often
reveals (peri-)vascular inflammation involving small arteries
and capillaries with variable cellular infiltrates, C3 deposition
and intravascular thrombi (1, 5). In one patient, granulomatous
nodular dermatitis and secondary fibrosis were observed.
Pulmonary involvement was also common (69.6%), most
frequently manifesting as ILD (64.3%) with infiltrative interstitial
opacification in the lung periphery on CT-scan. In a substantial
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number of cases (30.4%), ILD progressed to pulmonary fibrosis.
Other manifestations included intrathoracic lymphadenopathy
(17.9%). Lung biopsies performed in 28.6% predominantly
identified lymphocytic infiltrates surrounding alveoli and
bronchioles (1–3).
STING-associated vasculopathy with onset in infancy patients
are susceptible to soft tissue (35.7%) and respiratory tract (55.4%)
infections, which can be related to their underlying vascular or
pulmonary disease, as most patients had severe digital ischemia
or underlying ILD or fibrosis. However, SAVI itself may carry
an infectious susceptibility as a considerable percentage of
patients had lymphopenia, leukopenia or impaired lymphocyte
proliferation tests (1, 2, 6). Immunophenotyping in our proband
also showed CD4 + T-cell, NK-cell lymphopenia and impaired
T-cell proliferation (Supplementary Table E1). Arthralgia,
myalgia and arthritis, mainly affecting the small joints, were
noted in a 21.4% of patients. Renal manifestations are rare
(7.1%). One patient of African-American ethnicity, presenting
with skin vasculopathy and ILD, developed generalized edema
due to nephrotic range proteinuria at the age of 14 months
(4). Renal biopsy showed focal segmental glomerulosclerosis
(4). Of note, this patient also carried two APOL1 risk
variants which are associated with this kidney disease. Another
patient had mild renal involvement with microscopic hematuria
and hypertension requiring treatment (7). However, no renal
biopsy was performed. In our kindred, a pauci-immune intra-
and extra-capillary glomerulonephritis with proteinuria and
hematuria was observed.
Blood analysis across SAVI patients typically showed elevated
C-reactive protein and sedimentation rate (67.9%), indicating
systemic inflammation. Auto-immune serology was often
determined and up to 62% of SAVI patients had positive
autoantibodies (Supplementary Figure E1) mostly anti-nuclear
antibody, followed by ANCA, anti-cardiolipin antibody,
lupus anticoagulant, and anti-phospholipid antibody. These
autoantibodies confound the diagnosis of SAVI, as some patients
are initially classified as systemic lupus or ANCA-vasculitis (8)
patients based on their presentation and serology.
Treatment with corticosteroids, disease-modifying anti-
rheumatic drugs, anti-TNF, anti-CD20 and intravenous
immunoglobulins in SAVI patients has had limited or no effect.
Based on the pathophysiology, treatment with JAK-inhibitors
was evaluated in a number of patients with, albeit with varying
success (see Supplementary Document E1, available in the
online repository). In the patient described here, treatment
with rituximab, followed by glucocorticoids and azathioprine
resulted in a remission of his ocular features and partial
remission of renal disease up to 16 months of follow-up
(Supplementary Table E1).
CONCLUSION
STING-associated vasculopathy with onset in infancy was
initially identified in patients with early onset skin vasculopathy,
ILD and prominent systemic features caused by de novo or
familial gain-of-function mutations in STING. More recent
reports have indicated a wider phenotypic spectrum including
infectious, auto-immune, and even renal manifestations as in
our case, with considerable variability between and within
kindreds despite the presence of identical mutations. This clinical
heterogeneity remains to be explained.
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